
ELCC 2025: Amivantamab Plus Lazertinib Effective in EGFR-Mutated NSCLC Versus Standard of Care
In an interview with Pharmacy Times®, Nicolas Girard, MD, professor of respiratory medicine and thoracic oncology at the Claude Bernard University in Lyon, France, and senior attending physician in the thoracic oncology service of the Hospices Civils de …